Arbutus Biopharma Corp Stock Probability of Future Stock Price Finishing Over 10.76

ABUS Stock  USD 3.76  0.08  2.17%   
Arbutus Biopharma's future price is the expected price of Arbutus Biopharma instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Arbutus Biopharma Corp performance during a given time horizon utilizing its historical volatility. Check out Arbutus Biopharma Backtesting, Arbutus Biopharma Valuation, Arbutus Biopharma Correlation, Arbutus Biopharma Hype Analysis, Arbutus Biopharma Volatility, Arbutus Biopharma History as well as Arbutus Biopharma Performance.
  
Price Earnings To Growth Ratio is likely to gain to 1.38 in 2024, whereas Price To Sales Ratio is likely to drop 13.01 in 2024. Please specify Arbutus Biopharma's target price for which you would like Arbutus Biopharma odds to be computed.

Arbutus Biopharma Target Price Odds to finish over 10.76

The tendency of Arbutus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 10.76  or more in 90 days
 3.76 90 days 10.76 
close to zero percent
Based on a normal probability distribution, the odds of Arbutus Biopharma to move over $ 10.76  or more in 90 days from now is close to zero percent (This Arbutus Biopharma Corp probability density function shows the probability of Arbutus Stock to fall within a particular range of prices over 90 days) . Probability of Arbutus Biopharma Corp price to stay between its current price of $ 3.76  and $ 10.76  at the end of the 90-day period is about 65.28 .
Given the investment horizon of 90 days Arbutus Biopharma has a beta of 0.54. This suggests as returns on the market go up, Arbutus Biopharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Arbutus Biopharma Corp will be expected to be much smaller as well. Additionally Arbutus Biopharma Corp has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Arbutus Biopharma Price Density   
       Price  

Predictive Modules for Arbutus Biopharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Arbutus Biopharma Corp. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arbutus Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
1.323.756.18
Details
Intrinsic
Valuation
LowRealHigh
1.774.206.63
Details
Naive
Forecast
LowNextHigh
1.563.996.42
Details
5 Analysts
Consensus
LowTargetHigh
4.194.605.11
Details

Arbutus Biopharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Arbutus Biopharma is not an exception. The market had few large corrections towards the Arbutus Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Arbutus Biopharma Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Arbutus Biopharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.31
β
Beta against Dow Jones0.54
σ
Overall volatility
0.28
Ir
Information ratio -0.15

Arbutus Biopharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Arbutus Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Arbutus Biopharma Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Arbutus Biopharma generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 18.14 M. Net Loss for the year was (72.85 M) with loss before overhead, payroll, taxes, and interest of (45.39 M).
Arbutus Biopharma Corp currently holds about 150.2 M in cash with (85.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.0.
Arbutus Biopharma has a very weak financial position based on the latest SEC disclosures
Roughly 22.0% of the company shares are held by company insiders
Latest headline from insidermonkey.com: Disposition of 28000 shares by Sims Karen of Arbutus Biopharma at 4.57 subject to Rule 16b-3

Arbutus Biopharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Arbutus Stock often depends not only on the future outlook of the current and potential Arbutus Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Arbutus Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding166 M
Cash And Short Term Investments126 M

Arbutus Biopharma Technical Analysis

Arbutus Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Arbutus Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Arbutus Biopharma Corp. In general, you should focus on analyzing Arbutus Stock price patterns and their correlations with different microeconomic environments and drivers.

Arbutus Biopharma Predictive Forecast Models

Arbutus Biopharma's time-series forecasting models is one of many Arbutus Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Arbutus Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Arbutus Biopharma Corp

Checking the ongoing alerts about Arbutus Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Arbutus Biopharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Arbutus Biopharma generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 18.14 M. Net Loss for the year was (72.85 M) with loss before overhead, payroll, taxes, and interest of (45.39 M).
Arbutus Biopharma Corp currently holds about 150.2 M in cash with (85.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.0.
Arbutus Biopharma has a very weak financial position based on the latest SEC disclosures
Roughly 22.0% of the company shares are held by company insiders
Latest headline from insidermonkey.com: Disposition of 28000 shares by Sims Karen of Arbutus Biopharma at 4.57 subject to Rule 16b-3

Additional Tools for Arbutus Stock Analysis

When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.